# Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

> **NCT02435212** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 224 (actual)

## Conditions studied

- Transfusion-dependent Anemia

## Interventions

- **DRUG:** Deferasirox granule formulation
- **DRUG:** Deferasirox DT formulation

## Key facts

- **NCT ID:** NCT02435212
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-21
- **Primary completion:** 2018-05-31
- **Final completion:** 2024-01-15
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435212, "Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02435212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*